Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jerini To Submit Complete Response Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

With five companies in a race to control the HAE therapeutic space, three announce progress.
Advertisement

Related Content

Latest Dyax Deal For DX-88 Should Bring In $10 Million
ViroPharma Looks To Enter HAE Market With Lev Acquisition
Latest Dyax Deal For DX-88 Should Bring In $10 Million
ViroPharma Looks To Enter HAE Market With Lev Acquisition
Cubist Flexes Sales Force Built On Cubicin To Market AstraZeneca Anti-infective
Lev’s Cinryze Wins Unanimous Advisory Committee Support
Jerini’s Icatibant Falters in U.S., Wins In Europe
Jerini’s Icatibant Falters in U.S., Wins In Europe
Lev’s Cinryze To Get FDA Blood Products Advisory Committee Review
Jerini’s Firazyr For HAE Gets Advisory Committee Review Feb. 20

Topics

Advertisement
UsernamePublicRestriction

Register

PS067963

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel